These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Zugck C; Martinka P; Stöckl G Adv Ther; 2014 Sep; 31(9):961-74. PubMed ID: 25160945 [TBL] [Abstract][Full Text] [Related]
5. Doppler Echocardiography-Guided Heart Rate Modulation Therapy Using Ivabradine in a Patient with Systolic Heart Failure. Imamura T; Kinugawa K Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208489 [TBL] [Abstract][Full Text] [Related]
6. Implication of Ivabradine in Up-titrating Beta-blocker in a Patient with Advanced Heart Failure. Hori M; Imamura T; Nakamura M; Kinugawa K Intern Med; 2021 Mar; 60(6):897-900. PubMed ID: 33087678 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of ivabradine in Chinese patients with chronic heart failure: an observational study. Zhou J; Xu Y; Zheng Z; Zhang S; Yang J; Zhang Y; Tang B; Han H; Zhang Q; Liu F; Ding W; Qian C; Su G; Liu X; Shen Y; Shi B; Kong X; Ge Z; Zhang P; Guo X; Zhang H; Sun Y; Dong Y; Fu G; Feng L; Ge J; ESC Heart Fail; 2024 Apr; 11(2):846-858. PubMed ID: 38193606 [TBL] [Abstract][Full Text] [Related]
8. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study. Bagriy AE; Schukina EV; Samoilova OV; Pricolota OA; Malovichko SI; Pricolota AV; Bagriy EA Adv Ther; 2015 Feb; 32(2):108-19. PubMed ID: 25700807 [TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. Bouabdallaoui N; O'Meara E; Bernier V; Komajda M; Swedberg K; Tavazzi L; Borer JS; Bohm M; Ford I; Tardif JC ESC Heart Fail; 2019 Dec; 6(6):1199-1207. PubMed ID: 31591826 [TBL] [Abstract][Full Text] [Related]
10. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I; J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188 [TBL] [Abstract][Full Text] [Related]
11. Effects of ivabradine therapy on heart failure biomarkers. Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317 [TBL] [Abstract][Full Text] [Related]
12. Optimal Heart Rate Modulation Using Ivabradine. Imamura T; Kinugawa K Int Heart J; 2021 Jul; 62(4):717-721. PubMed ID: 34276025 [TBL] [Abstract][Full Text] [Related]
13. Prognosis of heart failure treated with digoxin or with ivabradine: A cohort study in the community. Guzman M; Gomez R; Romero SP; Aranda R; Andrey JL; Pedrosa MJ; Egido J; Gomez F Int J Clin Pract; 2018 Nov; 72(11):e13217. PubMed ID: 30248211 [TBL] [Abstract][Full Text] [Related]
14. The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. Hartmann C; Bosch NL; de Aragão Miguita L; Tierie E; Zytinski L; Baena CP Int J Clin Pharm; 2018 Dec; 40(6):1443-1453. PubMed ID: 30173307 [TBL] [Abstract][Full Text] [Related]
15. Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. Fiuzat M; Wojdyla D; Pina I; Adams K; Whellan D; O'Connor CM JACC Heart Fail; 2016 Feb; 4(2):109-115. PubMed ID: 26519996 [TBL] [Abstract][Full Text] [Related]
16. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. Bonnet D; Berger F; Jokinen E; Kantor PF; Daubeney PEF J Am Coll Cardiol; 2017 Sep; 70(10):1262-1272. PubMed ID: 28859790 [TBL] [Abstract][Full Text] [Related]
17. PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. Mentz RJ; DeVore AD; Tasissa G; Heitner JF; Piña IL; Lala A; Cole RT; Lanfear DD; Patel CB; Ginwalla M; Old W; Salacata AS; Bigelow R; Fonarow GC; Hernandez AF Am Heart J; 2020 May; 223():98-105. PubMed ID: 32217365 [TBL] [Abstract][Full Text] [Related]
18. Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction. Han SW; Choi SW; Ryu KH; Kim HJ; Kim SH; Shim WJ; Cha TJ; Choi DJ; Kim YJ; Yoo BS; Kim JH; Hwang KK; Jeon H; Shin MS Cardiovasc Ther; 2016 Jun; 34(3):172-9. PubMed ID: 27003232 [TBL] [Abstract][Full Text] [Related]
19. Heart Rate Control during Experimental Sepsis in Mice: Comparison of Ivabradine and β-Blockers. Bedet A; Voiriot G; Ternacle J; Marcos E; Adnot S; Derumeaux G; Mekontso Dessap A Anesthesiology; 2020 Feb; 132(2):321-329. PubMed ID: 31939847 [TBL] [Abstract][Full Text] [Related]
20. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study. Hidalgo FJ; Anguita M; Castillo JC; Rodríguez S; Pardo L; Durán E; Sánchez JJ; Ferreiro C; Pan M; Mesa D; Delgado M; Ruiz M Int J Cardiol; 2016 Aug; 217():7-11. PubMed ID: 27167103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]